Table 4.
Adjusted Odds Ratios (OR) of Baseline RAQ Scores Predicting Study Outcomes
| Baseline OR (95% CI) |
Week 26 OR (95% CI) |
Week 52 OR (95% CI) |
|
|---|---|---|---|
| Study Patient | |||
| Compliant based on pill check | NA | 2.74 (0.54 to 16.53) | 5.85* (1.34 to 25.54) |
| Study completion vs dropout | NA | ICS | 4.71* (1.01 to 21.95) |
| Enrollment in PK studiesb | 2.74 (0.88 to 8.55) | 2.99 (0.60 to 14.78) | 4.24 (0.86 to 1.76) |
| Study Partner | |||
| Compliant based on pill check | ICS | ICS | 1.98 (0.23 to 17.01) |
| Study completion vs dropout | ICS | ICS | 4.20** (1.71 to 10.32) |
| Enrollment in PK studiesa | ICS | 1.83 (0.17 to 19.38) | 1.65 (0.54 to 5.07) |
| Study Patient – Study Partner (PMD) | |||
| Compliant based on pill check | ICS | 5.05 (0.58 to 43.81) | 4.88 (0.43 to 55.29) |
| Study Completion vs dropout | ICS | ICS | 1.48 (0.21 to 10.65) |
| Enrollment in PK studiesa | 3.55 (0.32 to 39.27) | 2.10 (0.18 to 23.87) | 3.26 (0.30 to 35.11) |
Note. Trivariate analyses statistically control for study arm allocation and participant clustering within study site. Analyses exclude patients known to have died (n=3).
ICS = insufficient cell size; PK = pharmacokinetic; NA = No empirical cut point identified. PMD = Paired Mean Difference.
a
Subsample of participants at study sites that recruited at least one participant into PK studies (N=79). See Appendix 2.
*
≤0.05
**
≤0.01
***
≤0.001